6704.Two

The company's capital structure is characterized by a debt-to-equity ratio of 0.63, indicating a moderate reliance on debt financing. Its liquidity position is assessed as medium, with a current ratio of 1.98, suggesting it can cover short-term obligations but with limited excess capacity. The price-to-book ratio of 4.05 implies that the market values the company at a premium to its book value, which may reflect expectations of future growth or intangible assets.

Profitability metrics show a challenging performance, with a negative return on equity of -13.87% and a return on assets of -8.23%, both significantly below the industry median for pharmaceutical firms. The company reported a net loss of TWD 80,518,000 and an operating loss of TWD 73,669,000, indicating operational inefficiencies or high R&D costs. Gross profit of TWD 131,972,000 was insufficient to offset these losses, highlighting a need for cost optimization or revenue diversification.

Geographic and segment exposure is not explicitly detailed in the available data, but the company's revenue concentration is likely within its core pharmaceutical business. Given the absence of disclosed geographic breakdowns, it is unclear whether the company is exposed to regional regulatory or market risks. The lack of segment-specific data also limits the ability to assess the performance of individual product lines or therapeutic areas.

The company's growth trajectory is uncertain, with no specific outlook provided for the current or next fiscal year. However, the negative operating and free cash flows suggest a lack of immediate growth momentum. The company's capital expenditures of TWD 52,736,000 were not offset by positive cash generation, indicating reinvestment in operations or R&D. The absence of a clear revenue growth strategy or product pipeline details raises questions about long-term sustainability.

Risk factors include a negative net cash position after subtracting total debt, which could constrain operational flexibility and increase financial leverage. The company's liquidity risk is moderate, but the negative operating cash flow of TWD 27,982,000 and free cash flow of TWD 74,784,000 suggest ongoing cash burn. Credit risk is not explicitly quantified, but the negative earnings and cash flow metrics may affect the company's ability to secure favorable financing terms.

Recent events or filings are not detailed in the available data, but the company's financial performance and risk profile suggest a need for closer monitoring of its capital structure and operational efficiency. The absence of disclosed R&D milestones or regulatory approvals also limits visibility into potential catalysts for future growth.